Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae

Meridian Bioscience Inc. have signed a new agreement with Premier, Inc. to offer the complete illumigene^® molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.

The illumigene molecular system utilizes loop-mediated isothermal DNA amplification (LAMP) technology, an efficient system which allows Meridian to provide customers the illumipro–10™ instrument without a capital investment or costly annual service contract. The illumigene procedure is simple, highly sensitive, and yields results in less than one hour, which helps drive improvements in the early diagnosis and treatment of preventable diseases.